Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamol
The current work envisages synthesis of an ester prodrug of flurbiprofen whereby its carboxylic group was condensed with a skeletal muscle relaxant methocarbamol, with the aim of synergistic activity of two drugs, avoid flurbiprofen mediated gastro-intestinal damage and minimize the ulceration tende...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-06-01
|
| Series: | Asian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087615001312 |
| _version_ | 1828418905386778624 |
|---|---|
| author | Neela Bhatia Kiran Katkar Snehal Ashtekar |
| author_facet | Neela Bhatia Kiran Katkar Snehal Ashtekar |
| author_sort | Neela Bhatia |
| collection | DOAJ |
| description | The current work envisages synthesis of an ester prodrug of flurbiprofen whereby its carboxylic group was condensed with a skeletal muscle relaxant methocarbamol, with the aim of synergistic activity of two drugs, avoid flurbiprofen mediated gastro-intestinal damage and minimize the ulceration tendency of flurbiprofen. The synthesized prodrug was characterized and confirmed by physicochemical and spectroscopic studies. Solubility and partition coefficient studies indicated an increased lipophilicity and thus better suitability for oral administration than the parent drugs and the protein binding studies revealed a low protein binding capacity of the mutual prodrug. Subsequently, in-vitro hydrolysis was studied in different pH, simulated gastric fluid, simulated intestinal fluid and plasma and quantitative evaluation was performed by high performance liquid chromatography. It was found that the prodrug remained unhydrolyzed in the stomach after absorption however, underwent rapid cleavage by the esterases in blood to give the parent drug. Furthermore, the mutual ester prodrug was evaluated for its anti-inflammatory, analgesic, skeletal muscle relaxation, ulcerogenic and total acid content activity and was found to possess comparable activity with that of the parent drugs. Microscopic structures of the stomach tissues revealed significant reduction in gastric ulcer formation of mice gastric mucosa as compared to parent carboxylic acid drug. |
| first_indexed | 2024-12-10T14:44:14Z |
| format | Article |
| id | doaj.art-f9be098722fd464b859790662a45c6c6 |
| institution | Directory Open Access Journal |
| issn | 1818-0876 |
| language | English |
| last_indexed | 2024-12-10T14:44:14Z |
| publishDate | 2016-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-f9be098722fd464b859790662a45c6c62022-12-22T01:44:36ZengElsevierAsian Journal of Pharmaceutical Sciences1818-08762016-06-0111344945810.1016/j.ajps.2015.10.031Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamolNeela BhatiaKiran KatkarSnehal AshtekarThe current work envisages synthesis of an ester prodrug of flurbiprofen whereby its carboxylic group was condensed with a skeletal muscle relaxant methocarbamol, with the aim of synergistic activity of two drugs, avoid flurbiprofen mediated gastro-intestinal damage and minimize the ulceration tendency of flurbiprofen. The synthesized prodrug was characterized and confirmed by physicochemical and spectroscopic studies. Solubility and partition coefficient studies indicated an increased lipophilicity and thus better suitability for oral administration than the parent drugs and the protein binding studies revealed a low protein binding capacity of the mutual prodrug. Subsequently, in-vitro hydrolysis was studied in different pH, simulated gastric fluid, simulated intestinal fluid and plasma and quantitative evaluation was performed by high performance liquid chromatography. It was found that the prodrug remained unhydrolyzed in the stomach after absorption however, underwent rapid cleavage by the esterases in blood to give the parent drug. Furthermore, the mutual ester prodrug was evaluated for its anti-inflammatory, analgesic, skeletal muscle relaxation, ulcerogenic and total acid content activity and was found to possess comparable activity with that of the parent drugs. Microscopic structures of the stomach tissues revealed significant reduction in gastric ulcer formation of mice gastric mucosa as compared to parent carboxylic acid drug.http://www.sciencedirect.com/science/article/pii/S1818087615001312NSAIDsFlurbiprofenSkeletal muscle relaxantMethocarbamol, Ester prodrugRP-HPLCUlcerogenicity |
| spellingShingle | Neela Bhatia Kiran Katkar Snehal Ashtekar Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamol Asian Journal of Pharmaceutical Sciences NSAIDs Flurbiprofen Skeletal muscle relaxant Methocarbamol, Ester prodrug RP-HPLC Ulcerogenicity |
| title | Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamol |
| title_full | Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamol |
| title_fullStr | Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamol |
| title_full_unstemmed | Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamol |
| title_short | Formulation and evaluation of co-prodrug of flurbiprofen and methocarbamol |
| title_sort | formulation and evaluation of co prodrug of flurbiprofen and methocarbamol |
| topic | NSAIDs Flurbiprofen Skeletal muscle relaxant Methocarbamol, Ester prodrug RP-HPLC Ulcerogenicity |
| url | http://www.sciencedirect.com/science/article/pii/S1818087615001312 |
| work_keys_str_mv | AT neelabhatia formulationandevaluationofcoprodrugofflurbiprofenandmethocarbamol AT kirankatkar formulationandevaluationofcoprodrugofflurbiprofenandmethocarbamol AT snehalashtekar formulationandevaluationofcoprodrugofflurbiprofenandmethocarbamol |